SAMD8 Inhibitors
SAMD8 inhibitors represent a category of chemical compounds that interact with the Sterile Alpha Motif Domain-containing protein 8 (SAMD8). This protein is a member of the SAM domain family, which is known for a specific protein interaction module that is capable of binding to various partners and is implicated in a wide range of biological processes. SAMD8 itself is an enzyme that possesses both lipid phosphatase and transferase activities, playing a role in cellular lipid metabolism. The inhibitors of this enzyme are designed to specifically bind to SAMD8, thereby modulating its activity. These interactions can occur at various sites on the protein, including the active site where the enzyme's catalytic activity takes place, or at allosteric sites, which are distinct from the active site but can induce conformational changes that affect the protein's function.
The chemical construction of SAMD8 inhibitors is typically characterized by the presence of molecular features that enable the tight and selective binding to their target. These features can include hydrogen bond donors and acceptors, hydrophobic regions, and charged groups that match the binding pockets of SAMD8. The design of these molecules is often informed by the three-dimensional structure of SAMD8, with inhibitors being crafted to fit into the enzyme's binding sites much like a key fits into a lock. This lock-and-key interaction is crucial for the efficacy of an inhibitor, as it determines both the strength of the interaction (affinity) and the specificity (selectivity) for SAMD8 over other proteins. The development and refinement of SAMD8 inhibitors involve a complex interplay of chemistry, biochemistry, and structural biology, with the aim of achieving a high degree of interaction with the SAMD8 while minimizing off-target effects.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which indirectly modulates the activity of SAMD8 by influencing the PI3K/AKT signaling pathway, a route that can regulate sphingolipid metabolism and consequently SAMD8's role in this metabolic context. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
A neutral sphingomyelinase inhibitor that can impact sphingolipid metabolism. Since SAMD8 is involved in sphingolipid synthesis regulation, altering sphingolipid levels through this inhibitor could indirectly decrease SAMD8's functional activity. | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $150.00 | 8 | |
A potent inhibitor of serine palmitoyltransferase, the initial enzyme in sphingolipid synthesis. By reducing sphingolipid biosynthesis, Myriocin can indirectly affect the functional activity of SAMD8 in the sphingolipid metabolic pathway. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
An immunosuppressant that is phosphorylated in vivo to form a sphingosine-1-phosphate (S1P) analog, affecting S1P receptors and potentially altering the sphingolipid signaling environment in which SAMD8 operates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which reduces the activity of the MAPK/ERK pathway. This pathway can indirectly influence sphingolipid metabolism, thereby affecting the functional role of SAMD8. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that might indirectly reduce the activity of SAMD8 by modulating the sphingolipid metabolism signaling pathways where p38 MAPK plays a contributory role. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which may impact cellular stress responses and, by extension, the regulation of lipid metabolic processes involving SAMD8. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $189.00 $575.00 | 7 | |
A phosphatidylcholine-specific phospholipase C inhibitor, which may affect the generation of diacylglycerol from phosphatidylcholine, a process that could indirectly modulate SAMD8 activity. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
A farnesyltransferase inhibitor that impedes the post-translational modification of some proteins. As SAMD8 is associated with lipid signaling pathways, altering protein prenylation may indirectly influence its activity. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Another farnesyltransferase inhibitor that could impact the function of SAMD8 indirectly by modulating the prenylation of proteins integral to the regulation of lipid metabolism and signaling pathways. | ||||||